Accuracy of rapid point-of-care antibody test in patients with suspected or confirmed COVID-19 - 05/01/22
Doi : 10.1016/j.jinf.2021.07.006
Rama Vancheeswaran 2, Merlin Luke Willcox 1, ⁎ 
, Beth Stuart 1, Matthew Knight 2, Hala Kandil 2, Andrew Barlow 2, Mayon Haresh Patel 2, Jade Stockham 2, Aisling O'Neill 2, Tristan W Clark 1, Tom Wilkinson 1, Paul Little 1, Nick Francis 1, Gareth Griffiths 1, Michael Moore 1
, Beth Stuart 1, Matthew Knight 2, Hala Kandil 2, Andrew Barlow 2, Mayon Haresh Patel 2, Jade Stockham 2, Aisling O'Neill 2, Tristan W Clark 1, Tom Wilkinson 1, Paul Little 1, Nick Francis 1, Gareth Griffiths 1, Michael Moore 1 a University of Southampton Faculty of Medicine, Southampton, United Kingdom
b West Hertfordshire Hospitals NHS Trust, Watford General Hospital, Vicarage Road, Watford WD18 0HB
⁎Corresponding author.
Bienvenue sur EM-consulte, la référence des professionnels de santé.
Article gratuit.
Connectez-vous pour en bénéficier!
Highlights |
• | The rapid test for antibodies to SARS-COV-2 was 90.1% sensitive and 100% specific. |
• | This is comparable to reference antibody tests for prior infection with COVID-19. |
• | It could support clinical decision-making for patients with >10 days of symptoms. |
• | It would be useful in settings where vaccination is not widespread. |
• | And where PCR tests are not widely available. |
Keywords : COVID-19, Rapid antibody test, Point-of-care, Lateral flow immunoassay, Sensitivity, Specificity
© 2021
Publié par Elsevier Masson SAS.
Vol 84 - N° 1
P. 94-118 - janvier 2022 Retour au numéro
Article précédent
- N-acetylcysteine for the treatment of COVID-19 among hospitalized patients
- Sergey N. Avdeev, Viliya V. Gaynitdinova, Zamira M. Merzhoeva, Zelimkhan G.-M. Berikkhanov
- Is diffusion of SARS-CoV-2 variants of concern associated with different symptoms?
- Camilla Mattiuzzi, Brandon M. Henry, Giuseppe Lippi
Bienvenue sur EM-consulte, la référence des professionnels de santé.